Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyadenylate-binding protein cytoplasmic 1-like 2B (PABPC1L2B) is a predicted RNA-binding protein belonging to the poly(A)-binding protein family, which are known for binding the poly(A) tail of mRNA and promoting stability and translation[6][7]. While the best-studied member, PABPC1, supports cytoplasmic mRNA regulation, deadenylation, and translation, PABPC1L2B is predicted based on homology to share similar mRNA binding functions but lacks specific characterization. It is predicted to enable mRNA 3'-UTR, poly(A), and poly(U) RNA binding activity and is localized to extracellular exosomes[6][7]. There is currently no evidence it serves as a direct therapeutic target, biomarker, or that it interacts with any drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyadenylate-binding protein cytoplasmic 1-like 2B (PABPC1L2B).